1. Medtech Insight
  2. >>Archive

INTERVIEW: The bigger value picture behind Cardinal Health's Cordis buy

 
• By Tina Tan

When Johnson & Johnson agreed to sell Cordis to Cardinal Health for nearly $2bn last month, many saw Cardinal Health taking on a portfolio of mature medical devices – albeit of a well-established and globally recognized brand – that did not offer that much differentiation from the competition. So what’s in it for Cardinal Health and what’s the overriding objective behind the move? Tina Tan speaks to Don Casey, CEO of Cardinal Health’s Medical Segment, who spent nearly 26 years at J&J, to find out more about the underlying market changes and the strategy that motivated the company to make not only this particular acquisition, but likely more similar deals in the future

When Johnson & Johnson agreed to sell Cordis to Cardinal Health for nearly $2bn last month, many saw Cardinal Health taking on a portfolio of mature medical devices – albeit of a well-established and globally recognized brand – that did not offer that much differentiation from the competition. So what’s in it for Cardinal Health and what’s the overriding objective behind the move? Tina Tan speaks to Don Casey, CEO of Cardinal Health’s Medical Segment, who spent nearly 26 years at J&J, to find out more about the underlying market changes and the strategy that motivated the company to make not only this particular acquisition, but likely more similar deals in the future

In order to succeed in today’s budget-constrained healthcare environment, suppliers of medical devices are learning to push the value message to their customers

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

California Medtech Firms Resolve Patent Dispute Over Delivery Catheters

 
• By Brian Bossetta

Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.

Harbinger Health Targets High-Mortality Cancers First With AI-Driven MCED Platform

 
• By Shubham Singh

With a projected FDA submission within the next two to three years, Harbinger is prioritizing cancers based on lethality, prevalence, and unmet diagnostic need. Pancreatic and biliary cancers – often diagnosed at late stages and lacking established screening programs – will be among the initial targets.

Tariff Pressures Creep Into Dexcom’s Margin Outlook Despite Domestic Manufacturing Shield

 
• By Shubham Singh

Dexcom’s relatively strong position amid tariff-related uncertainty is rooted in its long-standing investments in domestic manufacturing, but raw material inflation is driving cost concerns even in the face of operational efficiencies.